SOURCE: BDI Pharma, Inc.

BDI Pharma, Inc.

January 10, 2011 07:30 ET

BDI Pharma Posts Record Revenues for 2010; Continues Successful Corporate Expansion

COLUMBIA, SC--(Marketwire - January 10, 2011) - BDI Pharma, Inc. (BDI), the nation's fastest growing national distributor of biotech therapies, announced that Sales Revenues for the twelve months of fiscal year 2010 represented an increase of more than twenty-six percent (26%) compared with the same period during calendar year 2009. Comparison of Units of Product Distributed year to year reflected a twenty-two percent (22%) for 2010 over 2009 as the successful expansion of BDI Pharma's product and service portfolio continued.

The Specialty Biopharmaceutical class of products, specifically in the clinical area of Oncology, grew nearly four-fold from 2009 to 2010, with equally significant increases in both branded and generic oncologics. Also notable from 2010 was continued growth within the Vaccine and the Protein Biotherapeutics classes, specific to the Influenza Vaccine, Hemophilia and Hyper-Immune product lines.

"In 2008, we at BDI Pharma began developing the framework for the expansion of our product portfolio and our corporate program offerings," said Edward Stiefel, Jr., Co-President of BDI Pharma. "Over the past two years, BDI Pharma has enjoyed the success of those initiatives, but we have also continued to both build upon and to expand that original framework. This commitment to strategic forethought combined with a willingness to challenge the marketplace's status quo has epitomized BDI Pharma from its inception, and will continue to do so in 2011 and beyond."

About BDI Pharma, Inc.

Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative inventory supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, www.bdipharma.com (www.ivig.com) has become an industry-renowned point of reference. Proprietary programs for veterinarians -- www.4legpharma.com; product consignment -- www.consignadvantage.com; flu vaccine pre-booking -- www.securiflu.com; vaccine ordering -- www.securivax.com; and purchasing/reward programs -- www.qoreprogram.com and www.securigam.com round out a family of solutions tailored to the needs of the healthcare community at large.

BDI Pharma's portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or "hyper" immune globulins, and other specialty injectables. BDI Pharma is recognized as an "ADR," or Authorized Distributor of Record, for all of the manufacturers it represents.

Contact Information

  • Contact:
    Brad Davis
    Assistant Vice President, Marketing
    (800)948-9834